• 1. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 4. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

Recent Advances in the Synthesis and Applications of tert-butyl 3-oxo-hexahydro-1H-[1,3]oxazolo[3,4-a]pyrazine-7-carboxylate (CAS: 935544-47-1)

The compound tert-butyl 3-oxo-hexahydro-1H-[1,3]oxazolo[3,4-a]pyrazine-7-carboxylate (CAS: 935544-47-1) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural features and potential applications in drug discovery. This heterocyclic scaffold, which combines an oxazolo-pyrazine core with a tert-butyl ester moiety, serves as a versatile intermediate for the synthesis of biologically active molecules. Recent studies have explored its utility in the development of protease inhibitors, GPCR modulators, and other therapeutic agents targeting complex diseases.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficient synthesis of this compound via a novel [4+2] cycloaddition strategy, achieving a 78% yield with high enantioselectivity (ee >95%). The researchers highlighted its role as a key building block for the construction of spirocyclic compounds with enhanced binding affinity to protein targets. Density functional theory (DFT) calculations supported the observed stereochemical outcomes, providing mechanistic insights into the reaction pathway.

In pharmacological applications, derivatives of 935544-47-1 have shown promising activity against neurological targets. A recent patent application (WO2023056421) disclosed its use in developing allosteric modulators of the mGluR5 receptor, with lead compounds exhibiting nanomolar potency and improved blood-brain barrier penetration compared to previous generations. Molecular docking studies revealed that the oxazolo-pyrazine core engages in critical hydrogen bonding interactions with Thr789 and Asp792 residues in the receptor's transmembrane domain.

The compound's stability profile has been systematically investigated through accelerated degradation studies under various pH conditions (pH 1-10). Results indicated exceptional stability in neutral to slightly basic environments (t_1/2 > 48 hours at pH 7.4), making it suitable for oral formulation development. However, researchers noted sensitivity to strong acids, necessitating protective group strategies during synthetic transformations.

Emerging applications in radiopharmaceuticals have been reported, where ¹⁸F-labeled derivatives of 935544-47-1 are being evaluated as PET tracers for imaging neuroinflammation. Preliminary biodistribution studies in rodent models showed favorable pharmacokinetics with rapid brain uptake (SUV_max = 2.1 at 15 min post-injection) and specific binding to activated microglia, as confirmed by autoradiography and immunohistochemistry.

Process chemistry advancements have addressed previous scalability challenges. A continuous flow chemistry approach published in Organic Process Research & Development (2024) achieved kilogram-scale production with 65% overall yield and >99.5% purity, eliminating the need for chromatographic purification. This development significantly enhances the compound's accessibility for industrial-scale drug development programs.

Future research directions include exploring the scaffold's potential in covalent inhibitor design through strategic incorporation of electrophilic warheads, as well as investigating its metal-chelating properties for antimicrobial applications. The compound's structural plasticity and demonstrated biological relevance position it as a valuable asset in modern medicinal chemistry campaigns targeting increasingly challenging therapeutic areas.

• 169448-87-7((R)-1-Boc-2-Hydroxymethyl-piperazine)
• 205434-75-9(Tert-butyl 2-(hydroxymethyl)piperazine-1-carboxylate)
• 301673-16-5(tert-butyl 3-(hydroxymethyl)piperazine-1-carboxylate)
• 1217728-72-7((S)-tert-Butyl 2-(methoxymethyl)piperazine-1-carboxylate)
• 143540-05-0(ditert-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate)
• 864448-41-9(Tert-butyl 3-oxa-7,9-diazabicyclo[3.3.1]nonane-7-carboxylate)
• 1023301-73-6(tert-butyl (2R)-2-(methoxymethyl)piperazine-1-carboxylate)
• 314741-40-7(tert-butyl (3S)-3-(hydroxymethyl)piperazine-1-carboxylate)
• 278788-66-2(tert-butyl (3R)-3-(hydroxymethyl)piperazine-1-carboxylate)
• 955400-16-5(tert-butyl (3S)-3-(methoxymethyl)piperazine-1-carboxylate)